VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
YCT-529
Phase 2
Small molecule
Y
YourChoice Therapeutics, Inc.
1
Indications
2
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Male Contraception
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Male Contraception
Phase 2
Recruiting
Clinical
Trials by Indication
[1]
Oral
1 trial
First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males
Completed
·
Y
YourChoice Therapeutics, Inc.
·
Phase 1
·
NCT06094283
·
16 enrolled
Unspecified
1 trial
Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males
Recruiting
·
Y
YourChoice Therapeutics, Inc.
·
Phase 1/2
·
NCT06542237
·
88 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
2 trial records for YCT-529. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
YCT-529 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for YCT-529. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
YourChoice Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 2
[1]
Company
Y
YourChoice Therapeutics, Inc.
Related News